PL3634975T3 - 17-oksymy 15.beta.-[3-propanamido]-podstawionych estra-1,3,5(10)-trien-17-onów do stosowania w hamowaniu aktywności 17.beta.-dehydrogenaz hydroksysteroidowych - Google Patents

17-oksymy 15.beta.-[3-propanamido]-podstawionych estra-1,3,5(10)-trien-17-onów do stosowania w hamowaniu aktywności 17.beta.-dehydrogenaz hydroksysteroidowych

Info

Publication number
PL3634975T3
PL3634975T3 PL18733926.2T PL18733926T PL3634975T3 PL 3634975 T3 PL3634975 T3 PL 3634975T3 PL 18733926 T PL18733926 T PL 18733926T PL 3634975 T3 PL3634975 T3 PL 3634975T3
Authority
PL
Poland
Prior art keywords
beta
propanamido
trien
oximes
inhibition
Prior art date
Application number
PL18733926.2T
Other languages
English (en)
Inventor
Leena HIRVELÄ
Marjo HAKOLA
Tero Linnanen
Pasi Koskimies
Camilla STJERNSCHANTZ
Original Assignee
Organon R&D Finland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon R&D Finland Ltd filed Critical Organon R&D Finland Ltd
Publication of PL3634975T3 publication Critical patent/PL3634975T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL18733926.2T 2017-06-08 2018-06-07 17-oksymy 15.beta.-[3-propanamido]-podstawionych estra-1,3,5(10)-trien-17-onów do stosowania w hamowaniu aktywności 17.beta.-dehydrogenaz hydroksysteroidowych PL3634975T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20175530 2017-06-08
PCT/FI2018/050427 WO2018224736A2 (en) 2017-06-08 2018-06-07 Therapeutically active steroidal derivatives

Publications (1)

Publication Number Publication Date
PL3634975T3 true PL3634975T3 (pl) 2024-07-01

Family

ID=62716091

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18733926.2T PL3634975T3 (pl) 2017-06-08 2018-06-07 17-oksymy 15.beta.-[3-propanamido]-podstawionych estra-1,3,5(10)-trien-17-onów do stosowania w hamowaniu aktywności 17.beta.-dehydrogenaz hydroksysteroidowych

Country Status (26)

Country Link
US (5) US10717761B2 (pl)
EP (1) EP3634975B1 (pl)
JP (3) JP7064515B2 (pl)
KR (1) KR102420512B1 (pl)
CN (2) CN115716860A (pl)
AU (1) AU2018279205B2 (pl)
CA (1) CA3066196C (pl)
CL (1) CL2019003562A1 (pl)
DK (1) DK3634975T3 (pl)
EA (1) EA201992826A1 (pl)
ES (1) ES2988187T3 (pl)
FI (1) FI3634975T3 (pl)
HR (1) HRP20240679T1 (pl)
HU (1) HUE066375T2 (pl)
IL (2) IL294140B2 (pl)
LT (1) LT3634975T (pl)
MX (2) MX2022000747A (pl)
NZ (1) NZ760155A (pl)
PL (1) PL3634975T3 (pl)
PT (1) PT3634975T (pl)
RS (1) RS65529B1 (pl)
SG (1) SG11201911776PA (pl)
SI (1) SI3634975T1 (pl)
UA (1) UA126342C2 (pl)
WO (1) WO2018224736A2 (pl)
ZA (1) ZA201908404B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7417608B2 (ja) * 2018-12-05 2024-01-18 フォレンド ファーマ リミテッド １７－ｈｓｄ１阻害剤としての１６（１７）位でピラゾール環と縮合しているエストラ－１，３，５（１０）－トリエン化合物
CN114644673B (zh) * 2020-12-19 2023-12-26 上海喀露蓝科技有限公司 一种雌二醇衍生物、其制备方法及其在医药上的用途
CN117264008A (zh) * 2022-06-15 2023-12-22 中国科学院大连化学物理研究所 一种化合物及应用和抑制剂与药物
CN120607578A (zh) * 2024-03-08 2025-09-09 长春金赛药业有限责任公司 17β-HSD1抑制剂化合物、药物组合物及其应用
WO2026057048A1 (zh) * 2024-09-13 2026-03-19 长春金赛药业有限责任公司 17β-HSD1抑制剂、药物组合物及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0101809A3 (en) 1998-03-11 2002-07-29 Endorech Inc Sainte Foy Inhibitors of type 5 and type 3 17betha-hydroxysteroid dehydrogenase and methods for their use
GB9929302D0 (en) 1999-12-11 2000-02-02 Univ Cardiff Benzyl tetralins compositions and uses thereof
PE20030703A1 (es) 2001-09-06 2003-08-21 Schering Corp Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3
EP1436281B1 (en) 2001-10-17 2010-06-16 Schering Corporation Piperidine- and piperazineacetamides as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2004046111A1 (en) 2002-11-18 2004-06-03 Schering Corporation 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DE60323765D1 (de) 2002-12-17 2008-11-06 Schering Corp Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
US7015211B2 (en) 2003-03-21 2006-03-21 Yale University 15α-substituted estradiol carboxylic acid esters as locally active estrogens
GB0306718D0 (en) 2003-03-24 2003-04-30 Sterix Ltd Compound
US20040224935A1 (en) 2003-04-07 2004-11-11 Endorecherche, Inc. Topical antiandrogenic steroids
US7465739B2 (en) 2003-06-10 2008-12-16 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US7754709B2 (en) 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
US8088758B2 (en) * 2003-11-12 2012-01-03 Abbott Products Gmbh 17β-hydroxysteroid dehydrogenase type I inhibitors
TWI331154B (en) * 2003-11-12 2010-10-01 Solvay Pharm Gmbh Novel 17-hydroxysteroid dehydrogenase type i inhibitors
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
DE102004032673A1 (de) 2004-07-02 2006-01-26 Schering Ag Neue 2-substituierte D-Homo-estra-1,3,5(10)-triene als Inhibitoren der 17ß-Hydroxysteroiddehydrogenase Typ 1
DE102004032674A1 (de) 2004-07-02 2006-01-26 Schering Ag Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1
US7575828B2 (en) 2004-07-23 2009-08-18 Kim Manufacturing Co. Modular rack assemblies for sealed lead acid batteries
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
CN101189251B (zh) * 2005-05-26 2012-09-12 索尔瓦药物有限公司 17β-HSD1和STS抑制剂
US8030298B2 (en) * 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
MX2009002579A (es) 2006-09-19 2009-03-20 Solvay Pharm Gmbh Derivados de estratrieno y sus usos como inhibidores de 17beta-hidroxiesteroide deshidrogenasa.
AU2007327653B2 (en) 2006-11-30 2013-04-18 Solvay Pharmaceuticals Gmbh Substituted estratrien derivatives as 17beta HSD inhibitors
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
WO2010059943A2 (en) 2008-11-20 2010-05-27 President And Fellows Of Harvard College Fluorination of organic compounds
US11072632B2 (en) * 2011-03-25 2021-07-27 UNIVERSITé LAVAL Inhibitors of 17β-HSD1, 17β-HSD3 and 17β-HSD10
JP6456373B2 (ja) * 2013-06-25 2019-01-23 フォレンド ファーマ リミテッド １７β−ヒドロキシステロイドデヒドロゲナーゼ タイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体
JP6556125B2 (ja) * 2013-06-25 2019-08-07 フォレンド ファーマ リミテッド １７β−ヒドロキシステロイドデヒドロゲナーゼの阻害剤としての治療的に活性な１７−窒素置換エストラトリエンチアゾール誘導体
TW201512215A (zh) * 2013-06-25 2015-04-01 Forendo Pharma Ltd 治療活性雌三烯噻唑衍生物
JP6545266B2 (ja) 2014-12-23 2019-07-17 フォレンド ファーマ リミテッド １７β‐ＨＳＤ１抑制剤のプロドラッグ
CN107207561B (zh) * 2014-12-23 2020-03-31 佛恩多制药有限公司 17β-HSD1–抑制剂的前药

Also Published As

Publication number Publication date
US20240309043A1 (en) 2024-09-19
MX2019014677A (es) 2022-04-01
JP2022065030A (ja) 2022-04-26
SG11201911776PA (en) 2020-01-30
LT3634975T (lt) 2024-06-25
EP3634975B1 (en) 2024-02-28
CL2019003562A1 (es) 2020-06-12
IL294140A (en) 2022-08-01
ES2988187T3 (es) 2024-11-19
AU2018279205A1 (en) 2020-01-16
US11254703B2 (en) 2022-02-22
CN110945007A (zh) 2020-03-31
CA3066196A1 (en) 2018-12-13
JP7664359B2 (ja) 2025-04-17
SI3634975T1 (sl) 2024-06-28
IL271218A (en) 2020-01-30
IL294140B2 (en) 2024-09-01
JP2020522539A (ja) 2020-07-30
US20180354984A1 (en) 2018-12-13
BR112019025782A2 (pt) 2020-06-23
NZ760155A (en) 2022-09-30
DK3634975T3 (da) 2024-05-27
CN115716860A (zh) 2023-02-28
KR20200023362A (ko) 2020-03-04
JP7401576B2 (ja) 2023-12-19
HRP20240679T1 (hr) 2024-08-16
MX2022000747A (es) 2023-01-24
US20200317718A1 (en) 2020-10-08
UA126342C2 (uk) 2022-09-21
US20250263431A1 (en) 2025-08-21
IL294140B1 (en) 2024-05-01
CA3066196C (en) 2023-08-29
WO2018224736A2 (en) 2018-12-13
US10717761B2 (en) 2020-07-21
RS65529B1 (sr) 2024-06-28
AU2018279205B2 (en) 2021-04-15
PT3634975T (pt) 2024-05-20
FI3634975T3 (fi) 2024-05-03
CN110945007B (zh) 2022-11-18
JP2024028916A (ja) 2024-03-05
MX391234B (es) 2025-03-21
JP7064515B2 (ja) 2022-05-10
US20220127303A1 (en) 2022-04-28
ZA201908404B (en) 2023-11-29
KR102420512B1 (ko) 2022-07-13
HUE066375T2 (hu) 2024-07-28
EP3634975A2 (en) 2020-04-15
WO2018224736A3 (en) 2019-01-17
EA201992826A1 (ru) 2020-05-14

Similar Documents

Publication Publication Date Title
IL285539A (en) Preparations containing 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in the treatment of mental disorders
IL271218A (en) 15 beta-[3-propanoamido] ester-1, 3, 5(10)-trien-17-one substances and their 17-oximes used in the inhibition of 17 beta-hydroxysteroid dehydrogenases
MX2019009842A (es) Composicion solida que comprende sofosbuvir amorfo.
MX367794B (es) Beta-caseína a2 y prevención de la inflamación del intestino.
IL240191A0 (en) Astra 5,3,1 (10),16-tetrane-3-carboxamides for inhibition of 17. beta-hydroxysteroid dehydrogenase (akr1 c3)
SG11201801534RA (en) 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof
MX2016008851A (es) Compuesto esteroideo para su uso en el tratamiento de encefalopatia hepatica.
GB2576614B (en) Compositions, uses and methods
ZA201905094B (en) Methods and microorganisms for making 2,3-butanediol and derivatives thereof from c1 carbons
GB2557319B (en) Toilet for use while squatting, components thereof, and processes for its manufacture
SI3402785T1 (sl) Derivati 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana
SG11202105012VA (en) Aromatic ring-linked dioxino-quinazoline or dioxino-quinoline compounds, compositions and use thereof
HUP1800441A1 (hu) Aktív szék, elsõsorban irodai használatra
GB201804163D0 (en) Uses, compositions and methods
MX2019009200A (es) Composiciones y métodos para inhibir el reticulón 4.
GB2579240B (en) New processes, compositions and medical uses
HK40020517A (en) 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
Keil Low emittance studies at 3 GeV at PETRA III
ZA201704287B (en) 3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of cns disorders
PH32018000784S1 (en) Chair (aversa)
მარიამ გაბისონია et al. ინტერვიუ
Subbanna Ella Kalakku Baruva Kathegalu-Shanta Rangachari-KV Subbanna
Sonbert Malefic Overtures
EP3634406C0 (en) 3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF
UA93055U (uk) Фармацевтична композиція для дентальної імплантації